Summary: Takeda has initiated a phase 3 trial of TAK-861, an oral orexin receptor 2 agonist, for narcolepsy type 1, marking progress in its late-stage pipeline. Phase 2b results showed that TAK-861 significantly improved wakefulness and reduced symptoms in narcolepsy patients, … [Read more...]